Skip to main content
AMCP 2025 Main banner
Back

Legislative and Regulatory Trends

(L2) Inflation Reduction Act Ripple Effects: Considerations for Patient Access and 340B

Tuesday, April 1, 2025
1:30 PM – 2:45 PM CST
Location: Grandballroom B
CPE
ACPE UAN:0233-0000-25-009-L03-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
The Inflation Reduction Act (IRA) will create a ripple effect across Medicare Part D formulary design, impacting multiple key stakeholders.  It is critical to understand potential unintended consequences of the IRA on these stakeholders, including patients, PBMs and health plans, and 340B covered entities. What does research evidence tell us about existing Part D access to Drug Price Negotiation Program (DPNP)-selected drugs and therapeutic alternatives? How will changing incentives amidst the IRA affect PBMs and health plans, and what will this mean for their business model and formulary design decisions? What will it mean for 340B covered entities and patients?  This session will explore the changing incentives in formulary structure and drug utilization as IRA implementation proceeds, with an eye toward patient access. Current research on access to DPNP-selected drugs and 2025 Part D formularies, as well as anticipated trends and impacts on healthcare stakeholders, will be discussed.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Discuss changing incentives for coverage of drugs selected to the IRA’s Drug Price Negotiation Program (DPNP) and their therapeutic alternatives as Maximum Fair Prices go into effect.
  2. Describe early signals of overall changes to Medicare Part D formulary coverage amidst the IRA’s Part D benefit redesign.
  3. Identify the potential impact of the DPNP on 340B margins and the likely impacts for patients at 340B covered entities.